HOOK - Hookipa Pharma Inc Stock Price, Fair Value and News

$2.50-0.08 (-3.10%)

Delayed as of 03 Dec 2024, 10:57 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

HOOK Price Action

Last 7 days

12.7%

Last 30 days

-32.8%

Last 90 days

-49.4%

Trailing 12 Months

-55.1%

HOOK RSI Chart

HOOK Valuation

Market Cap

31.1M

Price/Earnings (Trailing)

-0.72

Price/Sales (Trailing)

0.62

EV/EBITDA

0.72

Price/Free Cashflow

-0.46

HOOK Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

HOOK Fundamentals

HOOK Revenue

Revenue (TTM)

50.0M

Rev. Growth (Yr)

-31.51%

Rev. Growth (Qtr)

264.57%

HOOK Earnings

Earnings (TTM)

-43.4M

Earnings Growth (Yr)

27.4%

Earnings Growth (Qtr)

27.52%

HOOK Profitability

EBT Margin

-86.42%

Return on Equity

-60.43%

Return on Assets

-39.54%

Free Cashflow Yield

-218.25%

HOOK Investor Care

Shares Dilution (1Y)

43.59%

Diluted EPS (TTM)

-3.63

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	53.6M	52.2M	50.0M	0
2023	16.0M	15.9M	20.6M	20.1M
2022	14.6M	12.0M	10.3M	14.2M
2021	21.2M	19.9M	19.7M	18.4M
2020	13.4M	16.0M	18.0M	19.6M
2019	9.9M	13.3M	13.4M	11.9M
2018	0	0	0	7.6M

Get all data in R, Python etc through our Historical Stock Data APIs

About Hookipa Pharma Inc

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.

CEO	Mr. Joern Aldag
WEBSITE	hookipapharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	156

Hookipa Pharma Inc Frequently Asked Questions

What is the ticker symbol for Hookipa Pharma Inc? What does HOOK stand for in stocks?

HOOK is the stock ticker symbol of Hookipa Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hookipa Pharma Inc (HOOK)?

As of Mon Dec 02 2024, market cap of Hookipa Pharma Inc is 31.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOOK stock?

You can check HOOK's fair value in chart for subscribers.

Is Hookipa Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether HOOK is over valued or under valued. Whether Hookipa Pharma Inc is cheap or expensive depends on the assumptions which impact Hookipa Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOOK.

What is Hookipa Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, HOOK's PE ratio (Price to Earnings) is -0.72 and Price to Sales (PS) ratio is 0.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOOK PE ratio will change depending on the future growth rate expectations of investors.